NASDAQ:AMRN - Amarin Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.06 -0.04 (-1.29 %)
(As of 05/23/2018 01:37 AM ET)
Previous Close$3.06
Today's Range$3.03 - $3.18
52-Week Range$2.66 - $4.60
Volume2.81 million shs
Average Volume2.18 million shs
Market Capitalization$955.88 million
P/E Ratio-12.24
Dividend YieldN/A
Beta0.73

About Amarin (NASDAQ:AMRN)

Amarin logoAmarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers through direct sales force. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Debt-to-Equity Ratio-2.30
Current Ratio1.74
Quick Ratio1.45

Price-To-Earnings

Trailing P/E Ratio-12.24
Forward P/E Ratio-8.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.10 million
Price / Sales4.94
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-9.27

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-67,860,000.00
Net Margins-37.30%
Return on EquityN/A
Return on Assets-39.78%

Miscellaneous

Employees241
Outstanding Shares292,320,000

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. (NASDAQ:AMRN) released its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $43.80 million for the quarter, compared to the consensus estimate of $43.75 million. The firm's revenue for the quarter was up 26.6% on a year-over-year basis. During the same period last year, the company earned ($0.08) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

3 equities research analysts have issued 12-month target prices for Amarin's shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Amarin's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (5/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "Amarin announced the presentation of two posters at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX. These data, along with what we expect to be positive results from Amarin’s REDUCE-IT study by 3Q18, support our investment thesis for the stock. This is because a large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes." (4/12/2018)

Are investors shorting Amarin?

Amarin saw a decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,454,505 shares, a decrease of 54.3% from the April 13th total of 7,565,880 shares. Based on an average daily trading volume, of 3,165,407 shares, the days-to-cover ratio is presently 1.1 days.

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Chief Exec. Officer, Pres and Director (Age 57)
  • Mr. Michael W. Kalb CPA, Chief Financial Officer and Sr. VP (Age 47)
  • Dr. Steven B. Ketchum, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 53)
  • Mr. Joseph T. Kennedy J.D., Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)
  • Mr. Frederick W. Ahlholm CPA, Chief Accounting Officer and VP of Fin. & Admin. (Age 52)

Has Amarin been receiving favorable news coverage?

News headlines about AMRN stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amarin earned a coverage optimism score of 0.18 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (1.56%), Rock Springs Capital Management LP (1.37%), BlackRock Inc. (1.14%), Sofinnova Ventures Inc (1.14%), Alkeon Capital Management LLC (0.67%) and Opaleye Management Inc. (0.60%). Company insiders that own Amarin stock include John F Thero, Joseph T Kennedy and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP and California Public Employees Retirement System. Company insiders that have sold Amarin company stock in the last year include Joseph T Kennedy and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Ventures Inc, Alkeon Capital Management LLC, Opaleye Management Inc., Eversept Partners LLC, A.R.T. Advisors LLC, DekaBank Deutsche Girozentrale and Claraphi Advisory Network LLC. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $3.06.

How big of a company is Amarin?

Amarin has a market capitalization of $955.88 million and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  460 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amarin (NASDAQ:AMRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Amarin in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 194.12%. The high price target for AMRN is $10.00 and the low price target for AMRN is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$9.00
Price Target Upside: 194.12% upside190.32% upside146.58% upside154.96% upside

Amarin (NASDAQ:AMRN) Consensus Price Target History

Price Target History for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018Cantor FitzgeraldSet Price TargetBuy$10.00HighView Rating Details
3/1/2018HC WainwrightReiterated RatingBuyLowView Rating Details
10/11/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/19/2016CitigroupInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Amarin (NASDAQ:AMRN) Earnings History and Estimates Chart

Earnings by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.09)($0.05)($0.07)
Q2 20182($0.09)($0.08)($0.09)
Q3 20182($0.09)($0.09)($0.09)
Q4 20182($0.16)($0.09)($0.13)

Amarin (NASDAQ AMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018        
5/2/20183/31/2018($0.08)($0.08)$43.75 million$43.80 millionViewN/AView Earnings Details
2/27/2018n/a($0.05)($0.08)$52.73 million$53.87 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$45.85 million$47.10 millionViewN/AView Earnings Details
8/2/20176/30/2017($0.06)($0.05)$40.35 million$44.95 millionViewListenView Earnings Details
5/4/20173/31/2017($0.07)($0.08)$37.85 million$34.60 millionViewListenView Earnings Details
2/28/201712/31/2016($0.09)($0.05)$36.13 million$38.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.08)$32.03 million$32.40 millionViewN/AView Earnings Details
8/4/2016Q216($0.13)($0.07)$29.97 million$32.82 millionViewN/AView Earnings Details
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.08)($0.12)$23.62 million$26.40 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.18)$21.93 million$21.30 millionViewN/AView Earnings Details
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details
5/8/2015Q115($0.11)($0.18)$21.86 million$15.60 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details
11/6/2014Q314($0.14)($0.18)$14.87 million$14.15 millionViewN/AView Earnings Details
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details
5/9/2014Q114($0.18)($0.17)$11.65 million$11.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.15)($0.24)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.09)($0.15)ViewN/AView Earnings Details
2/29/2012Q4 2011($0.08)($0.08)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.13)($0.10)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.12)$2.51ViewN/AView Earnings Details
5/10/2011Q1 2011($0.08)($0.05)ViewN/AView Earnings Details
3/16/2011Q4 2010($0.08)$0.17ViewN/AView Earnings Details
9/25/2008Q2 2008$0.01ViewN/AView Earnings Details
5/19/2008Q4 2007($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amarin (NASDAQ:AMRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amarin (NASDAQ AMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.08%
Institutional Ownership Percentage: 42.50%
Insider Trading History for Amarin (NASDAQ:AMRN)
Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Joseph T KennedyGeneral CounselSell26,942$2.90$78,131.80View SEC Filing  
1/31/2018Joseph T KennedyGeneral CounselSell44,857$3.73$167,316.61View SEC Filing  
1/23/2018Steven B KetchumInsiderSell135,205$4.41$596,254.05View SEC Filing  
1/17/2018Joseph T KennedyGeneral CounselSell51,106$4.10$209,534.60View SEC Filing  
1/11/2018Steven B KetchumInsiderSell2,612$4.40$11,492.80View SEC Filing  
1/5/2018Steven B KetchumInsiderSell64,683$4.40$284,605.20View SEC Filing  
1/2/2018Steven B KetchumInsiderSell128,257$4.25$545,092.25View SEC Filing  
11/30/2017John F TheroInsiderBuy10,000$3.24$32,400.00View SEC Filing  
10/5/2017Steven B KetchumInsiderSell63,479$3.48$220,906.92View SEC Filing  
7/3/2017Joseph T. KennedyGeneral CounselSell307,911$4.00$1,231,644.00View SEC Filing  
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00661,743View SEC Filing  
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amarin (NASDAQ AMRN) News Headlines

Source:
DateHeadline
Reviewing Amarin (AMRN) & Aptevo Therapeutics (APVO)Reviewing Amarin (AMRN) & Aptevo Therapeutics (APVO)
www.americanbankingnews.com - May 21 at 7:14 PM
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
finance.yahoo.com - May 21 at 4:55 PM
Amarin Co. (AMRN) Receives Average Rating of "Hold" from BrokeragesAmarin Co. (AMRN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 21 at 1:36 AM
Amarin (AMRN) PT Set at $10.00 by Cantor FitzgeraldAmarin (AMRN) PT Set at $10.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 14 at 12:42 PM
Amarin (AMRN) versus Seres Therapeutics (MCRB) Head-To-Head AnalysisAmarin (AMRN) versus Seres Therapeutics (MCRB) Head-To-Head Analysis
www.americanbankingnews.com - May 12 at 3:29 PM
Amarin Co. (AMRN) Short Interest Down 54.3% in AprilAmarin Co. (AMRN) Short Interest Down 54.3% in April
www.americanbankingnews.com - May 12 at 1:06 AM
Amarin Co. (AMRN) Expected to Announce Quarterly Sales of $59.07 MillionAmarin Co. (AMRN) Expected to Announce Quarterly Sales of $59.07 Million
www.americanbankingnews.com - May 8 at 4:32 AM
Zacks Investment Research Upgrades Amarin (AMRN) to HoldZacks Investment Research Upgrades Amarin (AMRN) to Hold
www.americanbankingnews.com - May 7 at 5:28 PM
Analysts Set Expectations for Amarin Co.s Q3 2018 Earnings (AMRN)Analysts Set Expectations for Amarin Co.'s Q3 2018 Earnings (AMRN)
www.americanbankingnews.com - May 7 at 3:25 AM
Jefferies Group Brokers Reduce Earnings Estimates for Amarin Co. (AMRN)Jefferies Group Brokers Reduce Earnings Estimates for Amarin Co. (AMRN)
www.americanbankingnews.com - May 7 at 2:46 AM
Zacks: Brokerages Anticipate Amarin Co. (AMRN) Will Announce Earnings of -$0.08 Per ShareZacks: Brokerages Anticipate Amarin Co. (AMRN) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - May 6 at 3:14 AM
Amarin (AMRN) Raised to Sell at BidaskClubAmarin (AMRN) Raised to Sell at BidaskClub
www.americanbankingnews.com - May 5 at 1:01 AM
Amarin Co. Expected to Earn FY2021 Earnings of $0.02 Per Share (AMRN)Amarin Co. Expected to Earn FY2021 Earnings of $0.02 Per Share (AMRN)
www.americanbankingnews.com - May 4 at 10:36 AM
ValuEngine Upgrades Amarin (AMRN) to HoldValuEngine Upgrades Amarin (AMRN) to Hold
www.americanbankingnews.com - May 4 at 12:54 AM
Amarins (AMRN) CEO John Thero on Q1 2018 Results - Earnings Call TranscriptAmarin's (AMRN) CEO John Thero on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:39 AM
Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMTEdited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT
finance.yahoo.com - May 3 at 8:39 AM
Form 10-Q AMARIN CORP PLC\UK For: Mar 31Form 10-Q AMARIN CORP PLC\UK For: Mar 31
www.streetinsider.com - May 2 at 5:12 PM
Amarin Corporation PLC 2018 Q1 - Results - Earnings Call SlidesAmarin Corporation PLC 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 2 at 5:12 PM
Amarin (AMRN) Posts  Earnings Results, Misses Expectations By $0.01 EPSAmarin (AMRN) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 12:06 PM
Amarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald AnalystsAmarin (AMRN) Given a $10.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 2 at 12:00 PM
BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08
www.reuters.com - May 2 at 8:44 AM
Amarin Reports First Quarter 2018 Financial Results and Provides Update on OperationsAmarin Reports First Quarter 2018 Financial Results and Provides Update on Operations
finance.yahoo.com - May 2 at 8:44 AM
Amarin: 1Q Earnings SnapshotAmarin: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 8:44 AM
Amarin (AMRN) Set to Announce Earnings on WednesdayAmarin (AMRN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 28 at 11:06 AM
Amarin (AMRN) Downgraded to "Sell" at ValuEngineAmarin (AMRN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 26 at 2:04 PM
Amarin Co. (AMRN) Given Consensus Recommendation of "Hold" by AnalystsAmarin Co. (AMRN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 26 at 1:42 AM
$43.35 Million in Sales Expected for Amarin Co. (AMRN) This Quarter$43.35 Million in Sales Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 21 at 5:34 AM
-$0.07 Earnings Per Share Expected for Amarin Co. (AMRN) This Quarter-$0.07 Earnings Per Share Expected for Amarin Co. (AMRN) This Quarter
www.americanbankingnews.com - April 19 at 3:24 AM
Amarin (AMRN) Stock Rating Reaffirmed by Jefferies GroupAmarin (AMRN) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - April 13 at 11:43 PM
Amarins (AMRN) Buy Rating Reiterated at HC WainwrightAmarin's (AMRN) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 13 at 12:59 PM
Amarin Corp. (AMRN) Reports Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and ...Amarin Corp. (AMRN) Reports Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and ...
www.streetinsider.com - April 13 at 8:55 AM
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM ...New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM ...
globenewswire.com - April 13 at 8:55 AM
Moving Average Crossover Alert: Amarin (AMRN) April 12, 2018Moving Average Crossover Alert: Amarin (AMRN) April 12, 2018
www.zacks.com - April 12 at 5:11 PM
Moving Average Crossover Alert: Amarin (AMRN)Moving Average Crossover Alert: Amarin (AMRN)
finance.yahoo.com - April 12 at 5:11 PM
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific SessionsAmarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
finance.yahoo.com - April 12 at 5:11 PM
HC Wainwright Reaffirms "Buy" Rating for Amarin (AMRN)HC Wainwright Reaffirms "Buy" Rating for Amarin (AMRN)
www.americanbankingnews.com - April 12 at 3:58 PM
Cantor Fitzgerald Reiterates "$10.00" Price Target for Amarin (AMRN)Cantor Fitzgerald Reiterates "$10.00" Price Target for Amarin (AMRN)
www.americanbankingnews.com - April 12 at 11:39 AM
Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with ...Amarin presents posters in statin-treated patients with reduced kidney function and diabetes or elevated hsCRP with ...
seekingalpha.com - April 12 at 9:20 AM
Amarin: Waiting For REDUCE-IT ResultsAmarin: Waiting For REDUCE-IT Results
seekingalpha.com - April 11 at 9:07 AM
Amarin (AMRN) Downgraded by ValuEngine to SellAmarin (AMRN) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 10 at 7:51 PM
Amarin (AMRN) Upgraded to "Hold" by ValuEngineAmarin (AMRN) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 9 at 6:24 PM
FY2020 EPS Estimates for Amarin Co. (AMRN) Reduced by Jefferies GroupFY2020 EPS Estimates for Amarin Co. (AMRN) Reduced by Jefferies Group
www.americanbankingnews.com - April 9 at 2:30 AM
Wired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACEWired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
finance.yahoo.com - April 6 at 8:55 AM
Boom-or-Bust News Is On Tap Soon for AmarinBoom-or-Bust News Is On Tap Soon for Amarin
finance.yahoo.com - April 5 at 10:46 AM
Joseph T. Kennedy Sells 26,942 Shares of Amarin Co. (AMRN) StockJoseph T. Kennedy Sells 26,942 Shares of Amarin Co. (AMRN) Stock
www.americanbankingnews.com - April 4 at 1:28 PM
Amarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiativesAmarin updates Q1 revenue guidance and updates on REDUCE-IT study progress and Vascepa promotion initiatives
seekingalpha.com - April 4 at 8:47 AM
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT ...Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT ...
globenewswire.com - April 4 at 8:47 AM
Amarin Corp. (AMRN) Lowers 1Q18 Revenue Guidance to Approx. $43M (from $45M-$48M); Reiterates FY18 ...Amarin Corp. (AMRN) Lowers 1Q18 Revenue Guidance to Approx. $43M (from $45M-$48M); Reiterates FY18 ...
www.streetinsider.com - April 4 at 8:47 AM
BRIEF-Amarins says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of ...BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of ...
www.reuters.com - April 4 at 8:47 AM
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion InitiativesAmarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
finance.yahoo.com - April 4 at 8:47 AM

SEC Filings

Amarin (NASDAQ:AMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amarin (NASDAQ:AMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amarin (NASDAQ AMRN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.